strategy for baccarat

Rams’ Jordan Whittington providing a spark at kick returnerNoneUS stock indices pushed to fresh records Tuesday, shrugging off tariff threats from President-elect Donald Trump while European equities retreated. Trump, who doesn't take office until January 20, made his threat in social media posts Monday night, announcing huge import tariffs against neighbors Canada and Mexico and also rival China if they do not stop illegal immigration and drug smuggling. Both the Dow and S&P 500 notched all-time highs, with investors regarding the incoming president's words as a bargaining chip. "In theory, higher tariffs should not be good news for stocks. But, you know, I think the market's chosen to think of (it) as a negotiating tactic," said Steve Sosnick of Interactive Brokers. "You have bullish sentiment," said LBBW's Karl Haeling. "People are tending to look at things as positively as possible." But General Motors, which imports autos from Mexico to the United States, slumped 9.0 percent, while rival Ford dropped 2.6 percent. Overseas bourses were also buffeted by the news. European stocks followed losses in Asia, despite Trump excluding Europe as an immediate target for tariffs. "These are his first direct comments on tariffs and tariff levels since becoming president-elect, and they have roiled markets," said Kathleen Brooks, research director at XTB trading group, ahead of the Wall Street open. "It is early days, and there are plenty of opportunities for Trump to direct his attention to Europe down the line," Brooks added. The US dollar rallied against its Canadian equivalent, China's yuan and Mexico's peso, which hit its lowest level since August 2022. In other economic news, the Conference Board's consumer confidence index rose to 111.7 this month, up from 109.6 in October, boosted by greater optimism surrounding the labor market. "November's increase was mainly driven by more positive consumer assessments of the present situation, particularly regarding the labor market," said Dana Peterson, chief economist at The Conference Board. Pantheon Macroeconomics chief US economist Samuel Tombs added in a note that the increase in consumer confidence overall "likely was driven by euphoria among Republicans." "The index also jumped in late 2016, when Mr. Trump was elected for the first time," he said. Federal Reserve meeting minutes showed policy makers expect inflation to keep cooling, signaling a gradual approach to interest rate cuts if price increases ease further and the job market remains strong. New York - Dow: UP 0.3 percent at 44,860.31 (close) New York - S&P 500: UP 0.6 percent at 6,021.63 (close) New York - Nasdaq: UP 0.6 percent at 19,174.30 (close) London - FTSE 100: DOWN 0.4 percent at 8,258.61 (close) Paris - CAC 40: DOWN 0.9 percent at 7,194.51 (close) Frankfurt - DAX: DOWN 0.6 percent at 19,295.98 (close) Tokyo - Nikkei 225: DOWN 0.9 percent at 38,442.00 (close) Hong Kong - Hang Seng Index: FLAT at 19,159.20 (close) Shanghai - Composite: DOWN 0.1 percent at 3,259.76 (close) Euro/dollar: DOWN at $1.0482 from $1.0495 on Monday Pound/dollar: DOWN at $1.2567 from $1.2568 Dollar/yen: DOWN at 153.06 yen from 154.23 yen Euro/pound: DOWN at 83.41 pence from 83.51 pence Brent North Sea Crude: DOWN 0.3 percent at $72.81 per barrel West Texas Intermediate: DOWN 0.3 percent at $68.77 per barrel bur-jmb/st

AI voice cloning: How programs are learning to pick up on pitch and tone

Supermicro Shares Soar as It Looks to Avoid Being Delisted. Is Now a Good Time to Buy the Beaten-Down Stock?Canadian dollar up as stock markets rally ahead Christmas

Darnold gives Vikings another gem with career-high 377 yards in 27-25 win over Packers MINNEAPOLIS (AP) — Sam Darnold added another exploit to his career-altering season, passing for a personal-best 377 yards and three touchdowns as the Minnesota Vikings hung on to beat the Green Bay Packers 27-25 for their ninth consecutive victory. The Vikings are 14-2. They set up a final-week showdown in Detroit for both the division title and the No. 1 seed for the playoffs in the NFC. Jordan Love’s only touchdown pass for the Packers came with 2:18 left to pull the Packers within two points. Darnold responded with two completions for first downs to seal the game. Saquon Barkley tops 2,000 yards rushing and moves within 100 of Dickerson's record PHILADELPHIA (AP) — Saquon Barkley became the ninth running back in NFL history to top 2,000 yards rushing in a season, reaching the milestone with a 23-yard run in the fourth quarter against the Dallas Cowboys. That rush gave Barkley 2,005 yards with one game left and left him exactly 100 yards from Eric Dickerson’s record of 2,105, set in 1984 for the Los Angeles Rams. Barkley could potentially top the record in next week’s finale against the New York Giants. However, that game will be mostly meaningless for the Eagles, who could opt to rest Barkley to protect him from injury ahead of the playoffs. Moment of silence for former President Jimmy Carter held before the Falcons-Commanders game LANDOVER, Md. (AP) — A moment of silence was held for former President Jimmy Carter before the Atlanta Falcons' game at the Washington Commanders. The Georgia native served as the 39th president of the United States at the White House less than 10 miles away from 1977-81. Falcons owner Arthur Blank in a statement called Carter an inspirational global humanitarian. Carter died earlier Sunday at the age of 100 in Plains, Georgia. He also has a connection to the NFL as the first president to host the Super Bowl champions at the White House when he welcomed the Pittsburgh Steelers there in 1980. NFC's No. 1 seed comes down to Vikings-Lions showdown at Detroit in Week 18 The NFC’s No. 1 seed will come down to the final week when the Detroit Lions host the Minnesota Vikings. The winner takes the NFC North and gets a first-round playoff bye and home-field advantage until the Super Bowl. The loser gets the No. 5 seed and must play on the road in the wild-card round. The Vikings held on for a 27-25 victory over the Green Bay Packers to set up the high-stakes showdown in Week 18. The Lions visit the San Francisco 49ers on Monday night. Win, lose or tie, they have to beat the Vikings for a second time this season. Herro leads Heat over Rockets in game marred by fight and ejections in final minute HOUSTON (AP) — Tyler Herro scored 27 points before being one of six people ejected after a fight in the final minute of the Miami Heat’s 104-100 victory over the Houston Rockets on Sunday night. Herro was thrown to the ground by the Rockets’ Amen Thompson with 35 seconds left and the Heat leading 99-94. Players and coaches from both benches then came onto the court. Both players were thrown out along with Rockets guard Jalen Green, coach Ime Udoka and assistant coach Ben Sullivan. Terry Rozier was also ejected for Miami. Bills clinch the AFC's No. 2 seed with a 40-14 rout of the undisciplined Jets ORCHARD PARK, N.Y. (AP) — Josh Allen threw two touchdown passes and ran for another score and the Buffalo Bills clinched the AFC’s No. 2 seed with a 40-14 rout of the New York Jets. The Bills put the game away by capitalizing on two Jets turnovers and scoring three touchdowns over a 5:01 span in the closing minutes of the third quarter. Buffalo’s defense forced three takeaways overall and sacked Aaron Rodgers four times, including a 2-yard loss for a safety in the second quarter. The five-time defending AFC East champion Bills improved to 13-3 to match a franchise single-season record. Saquon Barkley tops 2,000 yards rushing as Eagles beat Cowboys 41-7 to clinch NFC East PHILADELPHIA (AP) — Saquon Barkley rushed for 167 yards to top 2,000 on the season, backup quarterback Kenny Pickett ran and threw for scores before departing with injured ribs, and the Philadelphia Eagles clinched the NFC East title by routing the Dallas Cowboys 41-7. Barkley has 2,005 yards and needs 101 in next week’s mostly meaningless regular-season finale to top Eric Dickerson and his 2,105 yards for the Los Angeles Rams in 1984. The Eagles led 24-7 in the third quarter when Pickett was drilled by defensive end Micah Parsons, ending his first start in place of the concussed Jalen Hurts. Penn State coach James Franklin says Nick Saban should be college football's commissioner SCOTTSDALE, Ariz. (AP) — Penn State coach James Franklin believes college football needs a commissioner and he even has a candidate in mind: former Alabama coach Nick Saban. Franklin made the suggestion Sunday at Penn State’s College Football Playoff quarterfinals media day ahead of the Fiesta Bowl. The sixth-seeded Nittany Lions are preparing for their game against No. 3 seed Boise State on Tuesday. The veteran coach was responding to a question about Penn State’s backup quarterback situation after Beau Pribula transferred to Missouri before the playoff. Pribula’s decision highlighted some of the frustrating aspects of a new college football world in the Name, Image and Likeness era and the transfer portal, forcing players to make tough decisions at inopportune times. LeBron James at 40: A milestone birthday arrives Monday for the NBA's all-time scoring leader When LeBron James broke another NBA record earlier this month, the one for most regular-season minutes played in a career, his Los Angeles Lakers teammates handled the moment in typical locker room fashion. They made fun of him. Dubbed The Kid from Akron, with a limitless future, James is now the 40-year-old from Los Angeles with wisps of gray in his beard, his milestone birthday coming Monday, one that will make him the first player in NBA history to play in his teens, 20s, 30s and 40s. He has stood and excelled in the spotlight his entire career. Rising Sun Devils: Arizona State looks to pull off another big surprise at the Peach Bowl ATLANTA (AP) — As they prepare for Arizona State’s biggest game in nearly three decades, the guys who made it happen aren’t the least bit surprised to be rated a nearly two-touchdown underdog in the College Football Playoff. That’s a familiar position for the Sun Devils. They've been an underdog most of the season. Of the eight teams still vying for a national championship, there’s no bigger surprise than 11-2 Arizona State. The Sun Devils went 3-9 a year ago and were picked to finish dead last in their first season in the Big 12 Conference. Now, they're getting ready to face Texas in the Peach Bowl quarterfinal game on New Year’s Day.

Neely scores 16 as Albany (NY) beats Stony Brook 77-70's most fantastic piece of hardware, the future-leaning Vision Pro, is not a success; not, at least, when measured on customer interest and market penetration. Throughout the year we've seen reports of though zero confirmation from Apple of sales numbers. The Cupertino tech giant mostly talks about developer support, the , , and third-party partner support. Most recently, Apple touted a . That price tag makes more sense when you consider that the Vision Pro still costs $3,499 / £3,499 / AU$5,999. As I've written from the start of my Vision Pro journey, . It's a spectacular mixed-reality experience that's as useful for as it is , where you can have a vast desktop of apps floating around your head. It's as intuitive as anything Apple has ever built, and you didn't think could be triggered by consumer electronics. It's also a system – we're not built to shut themselves off from each other. Wearing these goggles in the home elicits groans and serious side-eyes from family members and partners. I enjoyed the massive workspace in the office, but my coworkers thought I looked insane. Apple's efforts at virtual me staring back at friends, coworkers, and loved ones through the headset were also poorly received. I couldn't find anyone who wasn't turned off by my recreated gaze. Even those people who are inspired by the Vision Pro idea could barely afford it for the most part. $3,500 is not an "everyone" price, it's a "rarified few" one. I got a sense that Vision Pro wasn't taking a spot in homes in the US, and later around the world, when every time I wrote about the headset six people read the story. If we write about the (any make, model, or rumor) everyone reads it. The Vision Pro can't generate a fraction of the interest. I believe in the Vision Pro and the technology inside it. It's truly unlike anything else on the market or that I've experienced before, but it can't survive like this. Apple will surely be making some tough decisions in 2025. If, however, it wants the Vision Pro to survive, and not go the way of the or even the original , I have some notes. Reduce the price This is obvious, but it also means Apple taking a position it rarely does with hardware: a loss. It costs a lot to build the Vision Pro ( ), with the high-end displays maybe accounting for a third of that price. If Apple is not swapping out components (more on that later), it should simply cut the price by more than half and take the hit. Yes, each Vision Pro it sells in 2025 might cost it some money, but think of the millions who might buy it. Apple's growth is no longer built on hardware like the iPhone alone. It has a huge and rapidly growing services business, whereby you pay a monthly fee for access to storage, Apple TV Plus, Music, Fitness Plus, News, and so on. Apple customers buy more services when they have more Apple gadgets... you can see where this is going. Most of Apple's service experiences, like Apple TV Plus, are even better on a device like the Vision Pro, so this should represent a short-term loss that leads to a bigger long-term gain. Swap out materials and components What if the expected Vision Pro 2 features a plastic cover instead of glass? Does it need brushed aluminum? What if Apple does away with the displays driving the ? And maybe the resolution of the pricey display system could be lowered just a bit. Apple should look at all the ways it can reduce build costs without ruining the Vision Pro experience. I know that's a tall order, but the Vision Pro sometimes feels a bit overbuilt. To be fair, Apple did this because it was launching a new class of computing: spatial computing. The problem is that few others were buying the concept. Most consumers are still happy with regular old computing. To get them excited about it they need a cheaper Vision Pro, so fewer and cheaper materials and components might be one option. Ship an Apple Vision Lite Rumors point to arriving next year or the year after. If Apple is smart, it will tease a $1,500 Vision Pro Lite no later than March – disinterested consumers won't wait around for a late 2025 or 2026 launch. Apple needs to deliver affordable and usable Lite units fast enough to reboot the Vision Pro brand and finally start sucking in millions of new customers. Unveil Apple Vision AR glasses How does this help the Vision Pro? If these new lightweight are seen as part of the Vision Pro family, and they cost between $799 and $1,200, they might trigger a halo effect. Excitement and even some FOMO around the glasses could launch renewed interest in the overpriced mixed-reality headset, especially if the glasses also run and offer seamless integration with Vision Pro. Bundle Vision Pro with the iPhone 16 Pro Max 1 TB model An with 1TB of storage costs $1,599 / £1,599 / AU$2,849. That's a hefty mobile investment, and a signal to Apple that you are a devoted customer. What if when you buy that smartphone, Apple offers you a Vision Pro for an extra $599? That's far from free, but it is a massive discount for Apple's best-paying customers. Most people are buying the largest iPhone, and some might consider paying extra for all that storage if it also gave them access to a heavily discounted Vision Pro. I think Apple would be surprised at how many headsets it would end up moving. There's no perfect answer for how to save the Vision Pro, but I am certain that the solution revolves mostly around price. I think there are actually millions who would love to try the Vision Pro, but who see the price tag as a huge barrier and move on. Put the Vision Pro in reach of the masses, Apple, and you'll change the market equation, and save the Vision Pro in 2025.

ENGLEWOOD, Colo. (AP) — Losses to the Chargers and Bengals with a playoff berth on the line show Sean Payton made a miscalculation when he agreed to flex the Denver Broncos' Week 16 game to a Thursday night. Read this article for free: Already have an account? To continue reading, please subscribe: * ENGLEWOOD, Colo. (AP) — Losses to the Chargers and Bengals with a playoff berth on the line show Sean Payton made a miscalculation when he agreed to flex the Denver Broncos' Week 16 game to a Thursday night. Read unlimited articles for free today: Already have an account? ENGLEWOOD, Colo. (AP) — Losses to the Chargers and Bengals with a playoff berth on the line show Sean Payton made a miscalculation when he agreed to flex the Denver Broncos’ Week 16 game to a Thursday night. The NFL needed the Broncos’ approval to replace the Cincinnati-Cleveland game with the Broncos-Chargers game because Denver had already played on a Thursday night on the road. He eagerly agreed to the switch, figuring the team’s fanbase always travels well to SoFi Stadium in Los Angeles and the Broncos would be the more rested team at Cincinnati. But after an emotional comeback win over the Colts, the Broncos (9-7) lost to the Chargers in part because Payton got away from the run even though it helped them score touchdowns on their first three drives — and he had written “Run It!!” in marker on top of his play sheet. And they lost to the Bengals 30-24 in overtime on Saturday after Payton decided against going for 2 and the win when Marvin Mims Jr. hauled in a highlight-reel touchdown grab between two defenders with 8 seconds left in regulation. “We knew a tie for us was just as beneficial as a win,” Payton explained. “We felt like we had the momentum at that point.” Holding up two fingers, rookie QB Bo Nix lobbied for the 2-point try to no avail. “We discussed it all. We had plenty of time, plenty of time, plenty of time,” Payton said. “And the decision we made was the right one.” Well ... An extra point assured Joe Burrow would get the ball back, and the Broncos hadn’t forced a single punt all game, something Payton acknowledged afterward that he wasn’t aware of, and they hadn’t stopped the Bengals since twice holding them on fourth down in the first half. They finally forced a punt in overtime, but the Broncos went three-and-out, something they did again after Bengals kicker Cade York doinked a 33-yard field-goal attempt off the left upright on Cincinnati’s second possession. With the Bengals out of timeouts, all the Broncos needed was a first down and they’d be playoff-bound for the first time since 2015, but Bo Nix misfired to tight end Adam Trautman on third-and-long, so the Broncos punted and Burrow led the Bengals (8-8) on their game-winning touchdown drive. “I thought we could move the ball in overtime,” Nix said, “but we didn’t.” The Broncos could render all of it moot with a win in Week 18 against Kansas City with the Chiefs (15-1) expected to rely heavily on backups as they rest up for the playoffs as the AFC’s top seed. But Denver’s defense has been dismal since November, giving up the most yards in the league, and another letdown against the Chiefs would give the Broncos their biggest collapse in two decades. “This is what we do it for — meaningful games here,” Payton said. “I think it’s important that you embrace it, and it is exciting. There’s nothing worse than playing games in the last part of the season where there’s nothing at stake. So I think it’s something we’ll all be excited about.” What’s working Denver’s pass rush. The Broncos sacked Burrow seven times, giving them a league-high 58 for the season. Zach Allen had a career-best 3 1/2 of them and Dondrea Tillman’s sack gives the Broncos six players without at least five sacks this season. What needs help Riley Moss led the Broncos with 14 tackles but he had a tough return to action after missing a month with a sprained MCL. Burrow targeted him over and over, including on the game-winning touchdown throw to Tee Higgins, who caught three TD passes. “Riley could have been healthy for the last eight weeks. Whoever’s opposite Pat, they’re going to go that direction, right?” Payton said. (Higgins) is a good player. A real good player. It wasn’t anything that we didn’t expect. In other words, that happens when you’re teammates with Pat.” Stock up WR Marvin Mims Jr. had a breakout performance with eight catches for 103 yards and two fourth-quarter touchdowns, a 51-yarder and the 25-yard catch on fourth down in the closing seconds while sandwiched between two veteran defenders. Stock down Denver’s defense. Even with Moss back, which allowed DC Vance Joseph to go back to relying more on man coverage, the Broncos defense continued to struggle since the calendar turned to December. Injuries The Broncos came out healthy although superstar CB Patrick Surtain II was limping on the game’s final snaps. Key number Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. 5 — Number of NFL rookie QBs to throw for at least 3,000 yards and 25 touchdowns with Nix joining Justin Herbert, Baker Mayfield, Russell Wilson and Peyton Manning. What’s next It’s all or nothing next week when a win over the Chiefs would send Denver to the playoffs. ___ AP NFL: https://apnews.com/hub/NFL Advertisement Advertisement

BOGOTÁ, Colombia (AP) — El regreso del antiguo capo Fabio Ochoa a Colombia tras su deportación de Estados Unidos, donde pasó más de 20 años en prisión por narcotráfico , ha reabierto viejas heridas entre las víctimas del cártel de Medellín, y algunos han expresado consternación por la decisión de las autoridades colombianas de dejar a Ochoa en libertad. Algunas de las víctimas del cártel dijeron el martes que esperan que el excapo al menos coopere con los esfuerzos en curso de grupos de derechos humanos para investigar uno de los períodos más violentos de la historia de Colombia y desean que lo interroguen fiscales colombianos. A finales de la década de 1980 y principios de los 90, el cártel de Medellín mató a policías, políticos, jueces, periodistas y gente de a pie mientras libraba una guerra contra el Estado colombiano, el cual intensificó sus esfuerzos para interceptar envíos de drogas, arrestar a narcotraficantes y confiscar sus propiedades. Algunos historiadores en Colombia atribuyen 10.000 asesinatos al líder del cártel, Pablo Escobar. Ochoa, de 67 años, era uno de los operadores clave del grupo criminal en ese momento y vivió varios años en Miami, donde fue responsable de un centro de distribución de cocaína del cártel. Ochoa niega estar involucrado en los asesinatos del cártel. Pero muchas víctimas y sus familiares son muy escépticos respecto a esa afirmación. RELATED COVERAGE Un muerto tras impacto de misil ruso en edificio ucraniano En una rareza del calendario, Hanukkah comienza este año en Navidad Monitor global advierte que es inminente la hambruna en el norte de Gaza El actual alcalde de Bogotá, Carlos Fernando Galán, tenía 12 años cuando su padre, el candidato presidencial Luis Carlos Galán, fue asesinado por sicarios del cártel en 1989. El lunes por la noche, Galán escribió en un mensaje en la red social X donde dijo que es “inaceptable” que Ochoa no enfrentara ningún cargo en Colombia. El hermano mayor de Galán, Juan Manuel Galán, fue más allá: “La mayoría de sus crímenes (del cártel de Medellín) siguen impunes. Junto a miles de víctimas, esperamos conocer toda la verdad sobre su propia responsabilidad y la de sus aliados en asesinatos, secuestros y atentados terroristas indiscriminados”. Ochoa fue deportado a Colombia el lunes después de cumplir más de 20 años en prisión en Estados Unidos por una condena de tráfico de drogas, que no estaba relacionada con ningún asesinato en Colombia. Las autoridades le tomaron las huellas dactilares en el aeropuerto de Bogotá y quedó en libertad después de que funcionarios de inmigración que verificaron su nombre en una base de datos y confirmaron que no era buscado por las autoridades colombianas. Hablando con periodistas en el aeropuerto, que lo rodearon frenéticamente, Ochoa afirmó que había sido incriminado por los fiscales estadounidenses por un caso en el que “no soy culpable, me lo montaron”. Ochoa fue liberado en 1996, pero fue arrestado nuevamente en 1999 y extraditado a Estados Unidos en 2001 en respuesta a una acusación en Miami que lo nombraba a él y a más de 40 otros como parte de una conspiración de contrabando de drogas. Gonzalo Enrique Rojas era un niño en 1989, cuando su padre murió en un avión comercial que fue destruido por el cártel de Medellín, matando a las 107 personas a bordo. Rojas, quien ahora lidera una fundación para víctimas del conflicto en Colombia, dijo que el regreso de Ochoa a Colombia presenta una oportunidad para que se conozcan más detalles sobre ese incidente, como qué motivó al cártel a atacar un avión lleno de civiles y cuáles eran sus relaciones con miembros del gobierno colombiano. Dijo que los fiscales colombianos deberían interrogar a Ochoa sobre este evento y otros crímenes cometidos por el cártel. Añadió que su fundación, Colombia con Memoria, también intentará buscar una reunión con el antiguo capo. “Yo creo que los años de prisión terminan siendo indiferentes para quien fuimos víctimas del cártel de Medellín. Yo creo que realmente lo que repare, digámoslo el dolor o el hecho, es la verdad y la justicia”. ___ Esta historia fue traducida del inglés por un editor de AP con la ayuda de una herramienta de inteligencia artificial generativa.Enterprise Mobility Management (EMM) Market to grow by USD 75.37 Billion from 2024-2028, driven by BYOD adoption and AI impact on market trends - Technavio

What does the Israel-Hezbollah ceasefire include?Man accused in burning death of a woman on New York subway appears in court

Elon Musk visits US Congress to discuss plans to dramatically cut federal spending

MELBOURNE, Australia and INDIANAPOLIS , Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®[1], 89 Zr- girentuximab) kidney cancer imaging[2]. TLX250-CDx is an investigational PET[3] drug product for the non-invasive diagnosis and characterisation of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix's successful urology imaging franchise. The FDA is expected to advise the PDUFA[4] goal date following the 60-day administrative review of the application. Kevin Richardson , Chief Executive Officer, Precision Medicine at Telix, stated, "We are pleased to be progressing the BLA for TLX250-CDx, which has been granted Breakthrough designation, and may therefore be eligible for priority review. Telix continues to target a full U.S. commercial launch in 2025 addressing a major unmet medical need for patients with suspected ccRCC." About TLX250-CDx TLX250-CDx (Zircaix® 1 ) is an investigational PET agent that is under development for the diagnosis and characterisation of ccRCC. Telix's pivotal Phase III ZIRCON trial (ClinicalTrials.gov ID: NCT03849118 ) evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive-predictive value for ccRCC across three independent radiology readers[5]. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterising ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia , with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's lead imaging product, gallium-68 ( 68 Ga) gozetotide injection (also known as 68 Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[6], by the Australian Therapeutic Goods Administration (TGA) [7], and by Health Canada [8] . No other Telix product has received a marketing authorisation in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn . Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: [email protected] This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States . The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix® and Zircaix® 1 names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. [1] Brand name subject to final regulatory approval. [2] Telix ASX disclosure 31 July 2024. The FDA requested additional data demonstrating adequate sterility assurance during dispensing of TLX250-CDx in the radiopharmacy production environment. [3] Positron emission tomography. [4] Prescription Drug User Fee Act. [5] Shuch et al. Lancet Oncol. 2024. Telix ASX disclosures 7 November 2022. [6] Telix ASX disclosure 20 December 2021. [7] Telix ASX disclosure 2 November 2021. [8] Telix ASX disclosure 14 October 2022. SOURCE Telix Pharmaceuticals Limited